Ebsteins anomaly of the tricuspid valve risk factors: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The development of Ebstein's anomaly is associated with the administration of [[Lithium]] Carbonate during the first trimester or [[benzodiazepines]] during pregnancy. Maternal exposure to varnishing substances is also a risk factor as is a previous history of fetal loss in the mother. | |||
==References== | ==References== | ||
Revision as of 19:26, 20 October 2012
|
Ebsteins anomaly of the tricuspid valve Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Ebsteins anomaly of the tricuspid valve risk factors On the Web | |
|
American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve risk factors | |
|
Ebsteins anomaly of the tricuspid valve risk factors in the news | |
|
Blogs on Ebsteins anomaly of the tricuspid valve risk factors | |
|
Risk calculators and risk factors for Ebsteins anomaly of the tricuspid valve risk factors | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Claudia P. Hochberg, M.D.
Overview
The development of Ebstein's anomaly is associated with the administration of Lithium Carbonate during the first trimester or benzodiazepines during pregnancy. Maternal exposure to varnishing substances is also a risk factor as is a previous history of fetal loss in the mother.